Bio-Technology General Corp. Makes Key Executive Appointment.Business Editors ISELIN, N.J.--(BUSINESS WIRE)--Jan. 24, 2000 Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced that Dov Kanner, Ph.D. has been promoted to General Manager of BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group Ltd., the Company's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Rehovot, Israel, and Senior Vice President, BTG Corp. As General Manager of BTG Ltd., he now holds the most senior position within the subsidiary, reporting to the Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BTG Corp., Sim Fass. Dr. Kanner has held various positions since joining the Company in 1981, most recently that of Vice President, Quality Assurance and Regulatory Affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: Sim Fass, Chairman and CEO of Bio-Technology General Corp., stated: &uot;Dr. Kanner has had a long and outstanding career at BTG. He has broad management experience bridging a number of different disciplines, as well as first-hand knowledge of the Company's diverse operations. He is therefore eminently qualified to assume the most senior BTG Ltd. position. We look forward to benefiting from his future contributions to the success of the Company.&uot; Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered genetically engineered adjective Recombinant, see there and other products for human health care. The Company's products are marketed in over thirty countries worldwide. Statements in this news release concerning the Company's business outlook or future economic performance, anticipated profitability, revenues, expenses or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are &uot;forward-looking statements&uot; as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, patents owned by the Company and its competitors, and general economic conditions, as well as other risks detailed in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion